A Medical-Cannabis Review’s Evidence Did Not Cover Swallowed Oils Adequately
A review of medical-cannabis cognitive effects explicitly identified a shortage of research on orally ingested products, including oils. Its inhaled and sublingual evidence could not fill that route-specific gap.
The included routes were concentrated
The clinical studies used smoked or vaporized cannabis and sublingual or oromucosal spray preparations. The review’s limitations distinguish this evidence from research needed on ingested THC products. A product being medicinal does not make administration routes interchangeable.
Route changes the exposure question
Ingested and inhaled products differ in absorption and time course. The review consequently called for future oral-product trials rather than treating an inhalation-based recovery observation as a directly measured oil result. The gap concerns evidence available to this 2021 review, not a claim that no later oral research exists.
Historical scope should remain visible
The review can inform which functions were assessed in its selected clinical evidence. It cannot establish a universal interval for every swallowed formulation or reconstruct an individual’s exposure from a product category. Applying the synthesis to an oil, capsule or edible requires relevant route-specific data. This is a limitation on extrapolation, not proof that ingested THC always produces a particular longer or shorter impairment period. The actual preparation, dose and assessment schedule remain necessary to interpret a result.
Related analysis: the review’s broader findings and limitations.
Research cited
This analysis draws on the supplied review: Eadie and colleagues (2021). Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review. Frontiers in Psychiatry.
